Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.

A portrait of Subashan Vadibeler

 

Each year, the Lasker Foundation invites early career researchers to discuss big questions in biomedical research, with the aim of improving skills to communicate to a wide range of audiences. This year applicants were asked to 'Identify a specific unmet need in biomedical knowledge or a scientific question that is insufficiently addressed in biomedical research today'. 

Dr Subashan Vadibeler, a recent Oxford Rhodes scholar and MRes student who is supervised by by Assoc. Prof. Eileen Parkes and Prof. Tim Elliott, was one of five winners this year, receiving a $5000 stipend and the publication of his essay in The Journal of Clinical Investigation.

Commenting on the award, Subashan said: 

I spent 5 years training in medicine in urban and suburban settings of Malaysia's capital city, Kuala Lumpur where dengue is a disease with a huge disease burden. There was no escape from knowing the immunological basis behind the disease presentation, and it was frustrating that we have very little targeted intervention to offer for patients, mainly restricted by our limited understanding of the disease mechanism.

When I moved to Oxford to study immunology, I only became more interested in how viruses (and later, tumours) have evolved to evade our immune system in fascinating ways, with devastating consequences. I began to see the underlying immunological mechanism of severe dengue in everything I stumbled upon, including COVID-19 treatment/vaccines, cancer vaccines and immunotherapy. So, when Lasker Foundation this year asked about a  question that is insufficiently addressed by the scientific community, the answer was all to clear to me: antibody-dependent enhancement.

I am currently back in clinical practice, under the academic clinical training pathway, and I am very grateful to know that my research ideas born from clinical observation/experience is valued. Above that, I am grateful for the platform that this prize offers me, to share about a disease mechanism that has far-reaching significance that not everyone who has not been to the tropics has had the opportunity to witness first-hand. It is also a wonderful opportunity to share this in person later this year at the Lasker Award Ceremony in New York (my first time visiting the country). 

His essay, entitled 'The (unresolved) antibody paradox', discusses why prior infection doesn't always result in immune protection against re-infection, and can even make reinfection worse (so-called 'antibody-dependent enhancement'). Read Subashan's essay here

Similar stories

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Researchers develop easy-to-deploy federated learning system that safeguards patient data

The technique, which builds on recent advances in decentralised machine learning, uses inexpensive pre-programmed micro-computers, making it easy to deploy in hospitals and cheap to scale up.